Propanc Biopharma, Inc. (PPCB)
0.471
-0.03
(-5.55%)
USD |
NASDAQ |
Oct 08, 16:00
0.4635
-0.01
(-1.59%)
After-Hours: 20:00
Propanc Biopharma Enterprise Value : 1.236M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 1.236M |
| October 07, 2026 | 1.328M |
| October 06, 2026 | 1.304M |
| October 05, 2026 | 1.332M |
| October 02, 2026 | 1.357M |
| October 01, 2026 | 1.336M |
| September 30, 2026 | 1.313M |
| September 29, 2026 | 1.373M |
| September 28, 2026 | 1.443M |
| September 25, 2026 | 1.764M |
| September 24, 2026 | 1.670M |
| September 23, 2026 | 1.756M |
| September 22, 2026 | 1.832M |
| September 21, 2026 | 1.762M |
| September 18, 2026 | 1.697M |
| September 17, 2026 | 1.763M |
| September 16, 2026 | 1.780M |
| September 15, 2026 | 2.392M |
| September 14, 2026 | 2.491M |
| September 11, 2026 | 2.726M |
| September 10, 2026 | 2.798M |
| September 09, 2026 | 2.955M |
| September 08, 2026 | 3.087M |
| September 04, 2026 | 3.021M |
| September 03, 2026 | 3.054M |
| Date | Value |
|---|---|
| September 02, 2026 | 3.087M |
| September 01, 2026 | 3.418M |
| August 31, 2026 | 4.147M |
| August 28, 2026 | 4.147M |
| August 27, 2026 | 7.060M |
| August 26, 2026 | 3.220M |
| August 25, 2026 | 3.418M |
| August 24, 2026 | 3.501M |
| August 21, 2026 | 3.253M |
| August 20, 2026 | 3.319M |
| August 19, 2026 | 3.451M |
| August 18, 2026 | 3.518M |
| August 17, 2026 | 3.484M |
| August 14, 2026 | 3.716M |
| August 13, 2026 | 3.716M |
| August 12, 2026 | 3.683M |
| August 11, 2026 | 3.551M |
| August 10, 2026 | 3.484M |
| August 07, 2026 | 3.650M |
| August 06, 2026 | 4.180M |
| August 05, 2026 | 3.584M |
| August 04, 2026 | 3.054M |
| August 03, 2026 | 3.153M |
| July 31, 2026 | 3.021M |
| July 30, 2026 | 3.120M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Immutep Ltd. | -- |
| CSL Ltd. | -- |
| Ceryvyn Therapeutics Ltd. - ADR | -- |
| Mesoblast Ltd. | 1.828B |
| Actinogen Medical Ltd. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.573M |
| Total Expenses (Quarterly) | 4.573M |
| EPS Diluted (Quarterly) | -1.381 |
| Earnings Yield | -5.48K% |
| Normalized Earnings Yield | -5674.59 |